Chelsea Counsel Company’s GSK GSK Stock Holding History

Chelsea Counsel Company’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$495K	Hold	9,360	–	–	0.21%	67
2026 Q1	$521K	Hold	9,360	–	–	0.23%	67
2025 Q4	$463K	Hold	9,360	–	–	0.2%	64
2025 Q3	$408K	Hold	9,360	–	–	0.18%	76
2025 Q2	$363K	Hold	9,360	–	–	0.18%	80
2025 Q1	$366K	Sell	9,360 -20,000	-68%	-$732K	0.2%	78
2024 Q4	$1M	Hold	29,360	–	–	0.52%	42
2024 Q3	$1.21M	Hold	29,360	–	–	0.6%	39
2024 Q2	$1.14M	Hold	29,360	–	–	0.57%	38
2024 Q1	$1.27M	Hold	29,360	–	–	0.72%	34
2023 Q4	$1.1M	Hold	29,360	–	–	0.58%	40
2023 Q3	$1.07M	Hold	29,360	–	–	0.55%	40
2023 Q2	$1.06M	Hold	29,360	–	–	0.52%	42
2023 Q1	$1.05M	Hold	29,360	–	–	0.51%	44
2022 Q4	$1.04M	Hold	29,360	–	–	0.52%	46
2022 Q3	$864K	Hold	29,360	–	–	0.53%	49
2022 Q2	$1.6M	Hold	29,360	–	–	0.82%	31
2022 Q1	$1.6M	Hold	29,360	–	–	0.7%	37
2021 Q4	$1.62M	Hold	29,360	–	–	0.7%	36
2021 Q3	$1.4M	Hold	29,360	–	–	0.64%	38
2021 Q2	$1.46M	Hold	29,360	–	–	0.67%	38
2021 Q1	$1.31M	Hold	29,360	–	–	0.65%	41
2020 Q4	$1.35M	Hold	29,360	–	–	0.7%	39
2020 Q3	$1.38M	Hold	29,360	–	–	0.82%	36
2020 Q2	$1.5M	Hold	29,360	–	–	0.92%	33
2020 Q1	$1.39M	Hold	29,360	–	–	1.09%	30
2019 Q4	$1.73M	Hold	29,360	–	–	1.05%	30
2019 Q3	$1.57M	Hold	29,360	–	–	0.94%	31
2019 Q2	$1.47M	Hold	29,360	–	–	0.79%	37
2019 Q1	$1.53M	Hold	29,360	–	–	0.83%	36
2018 Q4	$1.4M	Hold	29,360	–	–	0.85%	34
2018 Q3	$1.47M	Hold	29,360	–	–	0.77%	37
2018 Q2	$1.48M	Buy	+29,360	New	+$1.48M	0.88%	37

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Chelsea Counsel Company's GSK Position: Q2 2026 in Review

Chelsea Counsel Company held its GSK (GSK) position steady in Q2 2026 at 9,360 shares worth $495K. The position accounts for 0.21% of the portfolio, ranked #67.

Chelsea Counsel Company first reported a position in GSK in Q2 2018 and has held it in 33 quarters since. The position peaked at $1.73M in Q4 2019. 1,042 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Chelsea Counsel Company held 9,360 shares of GSK worth $495K as of Q2 2026.
Chelsea Counsel Company left its GSK share count unchanged in Q2 2026.
GSK made up 0.21% of Chelsea Counsel Company's portfolio in Q2 2026, its #67 holding.
Chelsea Counsel Company first reported a position in GSK in Q2 2018 and has held it in 33 quarters since.
Chelsea Counsel Company's GSK position peaked at $1.73M in Q4 2019.
1,042 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Chelsea Counsel Company's 13F filing for Q2 2026, filed 12 Aug 2026.